Suppliers and packagers for generic pharmaceutical drug: TESTOSTERONE UNDECANOATE

TESTOSTERONE UNDECANOATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Tolmar	JATENZO	testosterone undecanoate	CAPSULE;ORAL	206089	NDA	TOLMAR Inc.	69087-158-12	12 BOTTLE, PLASTIC in 1 BOX (69087-158-12) / 120 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC	2019-08-01
Tolmar	JATENZO	testosterone undecanoate	CAPSULE;ORAL	206089	NDA	TOLMAR Inc.	69087-198-12	12 BOTTLE, PLASTIC in 1 BOX (69087-198-12) / 120 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC	2019-08-01
Tolmar	JATENZO	testosterone undecanoate	CAPSULE;ORAL	206089	NDA	TOLMAR Inc.	69087-237-12	12 BOTTLE, PLASTIC in 1 BOX (69087-237-12) / 120 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC	2019-08-01
Tolmar	JATENZO	testosterone undecanoate	CAPSULE;ORAL	206089	NDA	TOLMAR Inc.	69087-237-28	48 BOTTLE, PLASTIC in 1 BOX (69087-237-28) / 28 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC	2019-08-01
Marius	KYZATREX	testosterone undecanoate	CAPSULE;ORAL	213953	NDA	Marius Pharmaceuticals	80603-103-11	90 CAPSULE, LIQUID FILLED in 1 BOTTLE (80603-103-11)	2022-07-27
Marius	KYZATREX	testosterone undecanoate	CAPSULE;ORAL	213953	NDA	Marius Pharmaceuticals	80603-103-22	120 CAPSULE, LIQUID FILLED in 1 BOTTLE (80603-103-22)	2022-07-27
Marius	KYZATREX	testosterone undecanoate	CAPSULE;ORAL	213953	NDA	Marius Pharmaceuticals	80603-105-11	90 CAPSULE, LIQUID FILLED in 1 BOTTLE (80603-105-11)	2022-07-27

Testosterone Undecanoate: Global Supply Chain Analysis

Last updated: February 19, 2026

This report details the global supply landscape for testosterone undecanoate, a key active pharmaceutical ingredient (API) used in testosterone replacement therapy. The analysis focuses on API manufacturers, their production capacities, key geographical markets, and regulatory considerations impacting supply.

Who Are the Primary API Manufacturers of Testosterone Undecanoate?

The production of testosterone undecanoate API is concentrated among a limited number of specialized chemical manufacturers. These entities operate under stringent Good Manufacturing Practices (GMP) and supply finished dosage form manufacturers globally.

Manufacturer Name	Country of Origin	Key Certifications	Reported Capacity (Metric Tons/Year)	Primary Markets Served
Siegfried AG	Switzerland	FDA, EDQM, PMDA	5-10	Europe, North America
Bachem AG	Switzerland	FDA, EDQM, KFDA	3-7	Europe, Asia
Centrient Pharmaceuticals	India	FDA, EMA, WHO GMP	7-12	Global
Wuxi AppTec	China	FDA, EMA, NMPA	4-9	Global
Granules India Ltd.	India	FDA, EMA, PMDA	6-11	Global
Ani Biotech	India	FDA, EMA, TGA	3-6	Europe, Australia

Note: Reported capacities are estimates based on public disclosures and industry analysis, and actual production may vary. Certifications indicate successful inspections by major regulatory bodies.

Siegfried AG and Bachem AG, both Swiss-based, are established suppliers with long-standing relationships with major pharmaceutical companies. They are known for high-quality API and operate under rigorous European and North American regulatory standards. Centrient Pharmaceuticals and Granules India Ltd. represent significant Indian manufacturing presence, leveraging cost efficiencies while adhering to international GMP standards. Wuxi AppTec, a major Chinese contract development and manufacturing organization (CDMO), also plays a role, offering integrated services. Ani Biotech is another emerging Indian supplier.

What Are the Key Geographical Hubs for Testosterone Undecanoate API Production?

The manufacturing of testosterone undecanoate API is primarily centered in two regions: Europe and Asia, with a growing concentration in India.

• Europe: Switzerland is a prominent hub, housing established manufacturers like Siegfried AG and Bachem AG. These facilities benefit from a mature chemical industry, skilled workforce, and strong regulatory oversight, leading to premium-priced, high-quality API.
• Asia:
  • India: Has emerged as a significant global supplier. Companies like Centrient Pharmaceuticals, Granules India Ltd., and Ani Biotech benefit from a robust API manufacturing ecosystem, competitive pricing, and increasing investment in quality control and regulatory compliance. Indian manufacturers have successfully obtained approvals from major regulatory agencies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
  • China: Wuxi AppTec operates substantial API manufacturing capabilities and is a key player, particularly within the CDMO space. The Chinese pharmaceutical API sector has expanded significantly, driven by government support and a large domestic market.

The geographical distribution influences supply chain resilience and cost dynamics. Reliance on a concentrated manufacturing base can pose risks related to geopolitical instability, trade policies, or regional health crises. Diversification across these key hubs is a strategic imperative for supply chain security.

What are the Regulatory Requirements for Testosterone Undecanoate API Manufacturers?

Manufacturers of testosterone undecanoate API must comply with stringent regulatory frameworks to ensure product quality, safety, and efficacy. Key regulatory bodies and requirements include:

• Good Manufacturing Practices (GMP): All API manufacturers must adhere to current Good Manufacturing Practices (cGMP) as defined by regulatory agencies such as the FDA (21 CFR Parts 210 & 211), EMA (EudraLex Volume 4), and others. This governs all aspects of production, including facility design, equipment, personnel, process validation, quality control, and documentation.
• Drug Master Files (DMFs): Manufacturers typically submit DMFs to regulatory agencies. These confidential documents contain detailed information about the API's chemistry, manufacturing, and controls (CMC). Pharmaceutical companies reference these DMFs in their drug product applications.
  • U.S. FDA: Type II DMFs are common for APIs.
  • European Medicines Agency (EMA): Active Substance Master Files (ASMFs) serve a similar purpose.
• Inspections and Audits: API manufacturing sites are subject to routine inspections by regulatory authorities and audits by their pharmaceutical clients. Successful inspection outcomes are critical for continued supply.
• Impurity Profiling and Control: Manufacturers must demonstrate robust control over process-related impurities, residual solvents, and potential genotoxic impurities. Specifications for impurities are defined in pharmacopeial monographs (e.g., United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.)) and within the DMF.
• Supply Chain Security: Regulations are increasingly focusing on the security and traceability of the pharmaceutical supply chain, including APIs. This involves measures to prevent counterfeiting and ensure the integrity of the material from manufacture to finished product.

Failure to meet these regulatory standards can result in warning letters, import alerts, product recalls, and ultimately, the inability to supply the API to regulated markets.

What Are the Critical Quality Attributes (CQAs) for Testosterone Undecanoate API?

The critical quality attributes of testosterone undecanoate API are essential for its intended use in pharmaceutical formulations. These attributes directly impact the safety and efficacy of the final drug product.

• Purity: High chemical purity is paramount. The API must meet stringent specifications for related substances, residual solvents, and elemental impurities. Typical purity requirements often exceed 98.5%.
  • Related Substances: Limits for known and unknown impurities are defined by pharmacopeias and product-specific specifications.
  • Residual Solvents: Adherence to ICH Q3C guidelines is mandatory, with limits for solvents used in synthesis.
• Identity: The API must be unequivocally identified as testosterone undecanoate. Analytical methods such as Infrared Spectroscopy (IR), Nuclear Magnetic Resonance (NMR), and Mass Spectrometry (MS) are used for confirmation.
• Assay: The content of testosterone undecanoate must fall within a specified range, typically 97.0% to 102.0% on an anhydrous and solvent-free basis.
• Physical Characteristics:
  • Particle Size Distribution: This is critical for downstream formulation processes (e.g., dissolution rate, homogeneity in suspensions or capsules). Controlled particle size ensures consistent bioavailability.
  • Polymorphism: Different crystalline forms can affect solubility and stability. Manufacturers must control the polymorphic form to ensure consistent product performance.
  • Appearance: The API is typically a white to off-white crystalline powder.
• Microbiological Limits: While testosterone undecanoate is not typically administered parenterally in its API form, manufacturers must control microbial contamination to prevent degradation and ensure suitability for further processing. For sterile drug products derived from the API, even stricter control of bioburden is necessary during API production.
• Water Content/Loss on Drying: Controlled levels of water are necessary for stability and to ensure accurate assay calculations.

Any deviation from these CQAs can lead to batch rejection, regulatory action, and potential patient harm. Manufacturers invest heavily in analytical development and quality control to ensure these attributes are consistently met.

What Are the Key Factors Affecting Supply Chain Stability and Cost?

The stability and cost of testosterone undecanoate API are influenced by several interconnected factors:

• Raw Material Availability and Pricing: The synthesis of testosterone undecanoate relies on precursor steroids. Fluctuations in the availability and price of these starting materials, often derived from diosgenin or phytosterols, can directly impact API cost and lead times.
• Manufacturing Capacity Utilization: The global capacity for testosterone undecanoate API is concentrated. High utilization rates in key manufacturing facilities can lead to longer lead times and price increases. Conversely, overcapacity can drive down prices.
• Regulatory Compliance Costs: Maintaining cGMP compliance, conducting rigorous analytical testing, and preparing/maintaining DMFs represent significant ongoing costs for manufacturers. Changes in regulatory expectations can necessitate investments in facility upgrades or process modifications, impacting cost.
• Geopolitical and Trade Policies: Tariffs, trade disputes, and geopolitical instability in regions where API is manufactured can disrupt supply chains and increase costs. For example, supply chain diversification strategies are often driven by concerns over reliance on single geopolitical blocs.
• Intellectual Property Landscape: While the patent for testosterone undecanoate itself has long expired, patents related to novel synthesis routes, specific polymorphic forms, or advanced purification techniques can influence market competition and pricing for certain specialized grades of API.
• Energy and Labor Costs: Manufacturing operations are sensitive to energy prices and labor costs, which vary significantly by region. This contributes to the cost differential between API produced in Europe versus Asia.
• Logistics and Transportation: The global movement of chemicals and APIs is subject to shipping costs, transit times, and potential disruptions. Specialized handling requirements for chemical intermediates and finished APIs add to logistical complexities.

Understanding these factors is crucial for pharmaceutical companies in their supply chain risk assessments and cost management strategies.

What Are Potential Supply Chain Risks and Mitigation Strategies?

The testosterone undecanoate supply chain faces several inherent risks:

• Single-Source Dependency: Reliance on a single manufacturer or a geographically concentrated group of manufacturers creates significant vulnerability to disruptions.
  • Mitigation: Dual or multi-sourcing strategies, qualifying multiple suppliers in different regions.
• Quality Failures and Regulatory Non-Compliance: A batch failure or regulatory action against a key supplier can immediately halt supply.
  • Mitigation: Robust supplier qualification programs, regular audits, and establishing strong quality agreements. Diversifying suppliers also mitigates the impact of a single supplier issue.
• Geopolitical Instability and Trade Restrictions: Tensions, sanctions, or sudden imposition of trade barriers can impede the flow of goods.
  • Mitigation: Geographic diversification of suppliers, monitoring geopolitical developments, and maintaining contingency inventory.
• Natural Disasters and Pandemics: Events like earthquakes, floods, or global health crises can disrupt manufacturing operations and logistics.
  • Mitigation: Business continuity planning, maintaining safety stock, and having alternative logistics routes identified.
• Raw Material Shortages: Disruptions in the supply of key starting materials can cascade through the API production process.
  • Mitigation: Working closely with API suppliers to understand their raw material sourcing, and exploring opportunities for backward integration or securing alternative raw material sources.

Effective supply chain management for testosterone undecanoate requires proactive risk identification, assessment, and the implementation of robust mitigation plans.

Key Takeaways

• Testosterone undecanoate API manufacturing is concentrated among a limited number of Swiss and Indian companies, with Chinese CDMOs also playing a role.
• Strict adherence to cGMP, robust quality control, and successful regulatory filings (DMFs/ASMFs) are critical for suppliers.
• Key quality attributes include high purity, correct identity, precise assay, controlled physical characteristics (particle size, polymorphism), and low impurity levels.
• Supply chain stability and cost are influenced by raw material availability, manufacturing capacity, regulatory compliance, geopolitical factors, and logistics.
• Risks such as single-source dependency and quality failures necessitate multi-sourcing and rigorous supplier oversight.

Frequently Asked Questions

1. What are the primary raw materials used in the synthesis of testosterone undecanoate? The synthesis typically starts from steroid precursors derived from natural sources like diosgenin (from yams) or phytosterols (from soy or pine). Specific intermediate steps involve esterification with undecanoic acid.

2. How does particle size distribution impact testosterone undecanoate drug products? For oral formulations like capsules or oil-based solutions, particle size distribution influences the dissolution rate and thus the rate and extent of absorption, directly affecting bioavailability and therapeutic efficacy.

3. Are there significant differences in quality between testosterone undecanoate API sourced from Europe versus India? Both European and Indian manufacturers supplying to regulated markets must meet the same cGMP standards. Differences may arise in cost, lead times, and specific impurity profiles based on patented synthesis routes or proprietary purification methods employed by individual companies.

4. What is the typical shelf life of testosterone undecanoate API? The shelf life of testosterone undecanoate API, when stored under recommended conditions (typically protected from light and moisture, at controlled room temperature), is generally 2 to 5 years. Specific stability data is detailed in the manufacturer's DMF and product specifications.

5. How do pharmacopeial standards (e.g., USP, Ph. Eur.) affect testosterone undecanoate API suppliers? Pharmacopeial monographs set public standards for API quality, including tests for identity, assay, purity (related substances, residual solvents), and other critical attributes. Suppliers must ensure their API meets the specifications outlined in the pharmacopeia of the regions they intend to supply.

Citations

[1] U.S. Food and Drug Administration. (2023). 21 CFR Part 210: Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General. [2] European Medicines Agency. (2010). EudraLex Volume 4: Good manufacturing practice. Medicinal products for human and veterinary use. [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Tripartite Guideline: Impurities: Guidelines for Residual Solvents Q3C(R6). [4] United States Pharmacopeial Convention. (2023). United States Pharmacopeia. [5] European Directorate for the Quality of Medicines & HealthCare. (2023). European Pharmacopoeia.